Medicare’s Insulin Demo Project Likely Depends On Plan Interest
Manufacturers are on board for ‘Part D Senior Savings Model’ that would set a $35 copay cap, but added risk corridor payments may be the key to getting PBMs to offer the enhanced plans focused on reducing insulin costs for patients.
You may also be interested in...
The new payment demonstration in Part D reflects the increasing recognition that insurance benefit design has a major impact on insulin affordability.
Initiative aligns with IRS notice allowing high deductible health plans with health savings accounts to provide first dollar coverage for insulin and other glucose lowering agents before members have met their deductibles.
Study everything together and a scale-up manufacturing after preliminary efficacy results, former FDA commissioners Gottlieb and McClellan and their coauthors recommend in a pair of white papers on how the US should respond to the coronavirus pandemic.